AEP3 Antibody

What is the Anti-Prostaglandin E Receptor EP3 (PTGER3) Antibody?

The Anti-Prostaglandin E Receptor EP3 antibody is a highly specific immunological tool designed to recognize and bind to the EP3 receptor protein across multiple species. This antibody is typically generated against a specific epitope, such as the peptide sequence (C)RAPHWYASHMKTR, which corresponds to amino acid residues 137-149 of the mouse prostanoid EP3 receptor located in the second intracellular loop (Accession P34980) . The antibody's high specificity allows researchers to detect the expression and localization of EP3 receptors in various tissues including rat, mouse, and human samples. The development of such antibodies involves careful epitope selection to ensure minimal cross-reactivity with other prostaglandin receptor subtypes, providing reliable detection in experimental settings. Researchers can utilize this antibody in multiple applications including western blot analysis, immunohistochemistry, and flow cytometry, making it a versatile tool for investigating EP3 receptor biology .

What tissues and cell types express the EP3 receptor that can be detected with this antibody?

The EP3 receptor has been detected in numerous tissues and cell types using Anti-Prostaglandin E Receptor EP3 antibodies through various detection methods. Western blot analyses have confirmed significant EP3 receptor expression in rat kidney and pancreas membranes, as well as in mouse kidney membranes . In the central nervous system, EP3 receptor expression has been observed in neuronal processes within the parietal cortex, as demonstrated through immunohistochemical staining of perfusion-fixed frozen rat brain sections . A significant finding from double immunofluorescence studies revealed that almost all serotonergic cells in the medulla oblongata (B1-B4 cell groups) exhibit EP3 receptor-like immunoreactivity, while mesencephalic and pontine serotonergic cell groups (B5-B9) contain relatively smaller populations of EP3 receptor-immunoreactive cells . In catecholaminergic cell groups, many noradrenergic A7 cells in the subcoeruleus nucleus express the receptor, and the locus coeruleus exhibits dense EP3 receptor-like immunoreactivity in the neuropil and occasionally in neuronal cell bodies (all of which are dopamine β-hydroxylase-positive) . Additionally, human blood eosinophils have been reported to express EP3 receptors, and expression increases in astrocytes following lipopolysaccharide (LPS) stimulation .

What are the basic applications of Anti-EP3 antibodies in research settings?

Anti-Prostaglandin E Receptor EP3 antibodies serve multiple fundamental applications in research settings, primarily centered around protein detection and localization. Western blotting represents one of the most common applications, where the antibody has demonstrated effectiveness at dilutions of 1:200 for detecting EP3 receptor protein in membrane preparations from various tissues including rat kidney, pancreas, and mouse kidney . Immunohistochemical staining represents another crucial application, with the antibody showing excellent results at dilutions of 1:1000 for detecting EP3 receptor immunoreactivity in neuronal processes within rat brain sections, particularly in the parietal cortex . The antibody can also be employed in indirect flow cytometry for cell sorting and quantification of EP3 receptor-expressing cells. For specificity verification in experimental settings, researchers often conduct blocking experiments using specific peptides that compete with the antibody's binding site, such as the Prostaglandin E Receptor EP3/PTGER3 Blocking Peptide, which effectively suppresses antibody staining in control experiments . Additionally, these antibodies have proven valuable in tracking differential expression patterns under various physiological and pathological conditions, such as the observed increase in EP3 receptor expression in LPS-stimulated astrocytes .

What controls and validation steps are necessary for immunohistochemistry experiments using Anti-EP3 antibodies?

Implementing rigorous controls and validation steps is essential for ensuring the reliability of immunohistochemistry experiments using Anti-EP3 antibodies. Researchers should always include a peptide competition control, wherein the antibody is pre-incubated with the specific blocking peptide (Prostaglandin E Receptor EP3/PTGER3 Blocking Peptide) before application to tissue sections; this approach effectively suppresses specific staining, as demonstrated in experiments with rat brain sections where EP3 receptor immunoreactivity in neuronal processes was completely abolished following peptide blocking . Multiple dilution testing represents another critical validation step, with published protocols suggesting 1:1000 as an effective dilution for brain tissue sections, though optimal concentrations may vary depending on tissue type, fixation method, and detection system . When designing experiments, researchers should include positive control tissues with known EP3 receptor expression patterns, such as specific brain regions (parietal cortex) or kidney sections, to verify proper immunodetection . For co-localization studies, double immunofluorescence techniques combining the Anti-EP3 receptor antibody with antibodies against specific cellular markers (such as serotonergic or catecholaminergic neurons) can provide valuable information about the cellular distribution of EP3 receptors, as demonstrated in studies of rat brain monoaminergic nuclei . Additionally, researchers should consider complementary approaches such as in situ hybridization to correlate protein detection with mRNA expression patterns, providing multi-level validation of EP3 receptor localization findings.

How can researchers address potential cross-reactivity issues with Anti-EP3 antibodies?

Addressing potential cross-reactivity issues with Anti-EP3 antibodies requires implementing multiple strategic approaches to ensure experimental specificity and validity. Peptide competition assays serve as the gold standard for validating antibody specificity, wherein parallel experiments are conducted with the antibody alone and with the antibody pre-incubated with the specific blocking peptide (Prostaglandin E Receptor EP3/PTGER3 Blocking Peptide); complete elimination of signal in the presence of the blocking peptide strongly supports antibody specificity, as demonstrated in western blot analyses of rat kidney and pancreas membranes . Researchers should carefully evaluate the antibody's cross-reactivity profile against other prostaglandin receptor subtypes (EP1, EP2, EP4) through comparative analyses using recombinant proteins or cells expressing single receptor subtypes to confirm target selectivity. When working with novel tissue types or experimental conditions, researchers should validate findings using multiple detection methods, such as combining western blotting with immunohistochemistry or flow cytometry, to confirm consistent EP3 receptor expression patterns across different analytical platforms . For critical experiments, employing multiple Anti-EP3 antibodies targeting different epitopes of the receptor can provide complementary evidence for specific EP3 receptor detection, minimizing the risk of false-positive results due to individual antibody limitations. Additionally, researchers studying transgenic models with EP3 receptor knockouts or knockdowns should include these as negative controls to definitively establish antibody specificity by demonstrating the absence of signal in tissues lacking the target protein.

How should researchers interpret varying EP3 receptor expression patterns across different tissue types?

Interpreting varying EP3 receptor expression patterns across different tissue types requires careful consideration of both biological variables and methodological factors. Tissue-specific expression profiles reflect the diverse physiological roles of EP3 receptors, with particularly high expression observed in kidney, pancreas, and specific brain regions such as the medulla oblongata's serotonergic cells (B1-B4) and the locus coeruleus, suggesting important functions in renal, metabolic, and neurological processes respectively . When analyzing expression data, researchers should recognize that EP3 receptor expression is not uniformly distributed even within a single tissue type; for instance, in the brain, almost all serotonergic cells in the medulla oblongata express EP3 receptors, while only a subset of cells in mesencephalic and pontine serotonergic groups (B5-B9) show immunoreactivity, indicating region-specific regulatory mechanisms . The subcellular localization of EP3 receptors also varies by cell type, with some tissues showing primarily membrane localization while others, such as the locus coeruleus, exhibit dense immunoreactivity in the neuropil, necessitating high-resolution imaging techniques like confocal microscopy for accurate interpretation . Researchers should be aware that EP3 receptor expression is dynamic and can change in response to physiological stimuli, as evidenced by increased expression in astrocytes following LPS stimulation, suggesting that expression patterns should be interpreted in the context of the tissue's physiological or pathological state . Additionally, apparent contradictions in expression data between studies may reflect methodological differences in antibody sensitivity, tissue preparation, or detection methods, highlighting the importance of standardized protocols and appropriate controls in comparative analyses.

What physiological insights can be gained from EP3 receptor localization in monoaminergic neurons?

The localization of EP3 receptors in monoaminergic neurons provides significant physiological insights into prostaglandin-mediated regulation of neural circuits and behavior. The pronounced expression of EP3 receptors in serotonergic cells, particularly in the medulla oblongata (B1-B4 groups), suggests a direct mechanism through which inflammatory prostaglandins can modulate serotonergic neurotransmission, potentially impacting autonomic functions, pain processing, and mood regulation . The differential expression pattern observed across serotonergic cell groups, with nearly complete expression in medullary groups but limited expression in mesencephalic and pontine groups (B5-B9), indicates region-specific roles for EP3-mediated signaling within the serotonergic system, potentially contributing to selective serotonergic dysfunction in pathological conditions . In catecholaminergic neurons, the robust EP3 receptor expression in noradrenergic A7 cells of the subcoeruleus nucleus and in the locus coeruleus points to prostaglandin-dependent modulation of noradrenergic signaling, which could influence arousal, attention, stress responses, and autonomic regulation . The presence of EP3 receptors in both cell bodies and neuropil of monoaminergic neurons suggests that prostaglandin signaling may affect not only gene expression and cellular metabolism but also synaptic transmission and neural circuit function through pre- and post-synaptic mechanisms . These localization patterns provide a structural framework for understanding how inflammatory signals, via prostaglandin synthesis and EP3 receptor activation, can induce neuropsychiatric symptoms such as depression, anxiety, and cognitive impairment that are frequently associated with peripheral inflammatory conditions and centrally-mediated sickness behaviors.

How do researchers reconcile contradictory findings regarding EP3 receptor function in different pathological contexts?

Reconciling contradictory findings regarding EP3 receptor function across different pathological contexts requires a nuanced approach that considers molecular, cellular, and systemic variables. Context-dependent signaling represents a primary explanation for seemingly contradictory EP3 receptor functions; for instance, EP3 receptor activation appears to promote pathogenesis in pulmonary arterial hypertension through upregulation in pulmonary arterial smooth muscle cells under hypoxic conditions, while showing protective effects in other tissues, highlighting the importance of cell-type specific signaling pathways and microenvironmental factors . Receptor isoform diversity contributes significantly to functional variation, as the EP3 receptor exists in multiple splice variants with distinct C-terminal domains affecting G-protein coupling preferences and downstream signaling cascades; researchers should determine which isoforms predominate in their experimental system to accurately interpret functional data. In cancer biology, contradictory findings regarding EP3 receptor functions may reflect disease stage-specific effects, with studies showing decreased EP3 expression in invasive bladder cancer compared to normal urothelial cells, suggesting context-dependent tumor suppressive or promoting roles that vary with malignant progression . The integration of EP3 signaling with other receptor systems creates complex signaling networks that can produce different outcomes depending on the activation state of complementary pathways; this complexity necessitates comprehensive pathway analysis rather than isolated receptor studies. To address these contradictions methodologically, researchers should implement systems biology approaches combining transcriptomics, proteomics, and functional assays across multiple physiological conditions and cell types to develop integrated models of EP3 receptor function that can account for context-dependent effects observed in different pathological scenarios.

How can Anti-EP3 antibodies be utilized for studying receptor expression changes in inflammatory conditions?

Anti-EP3 antibodies offer powerful tools for investigating receptor expression changes during inflammatory conditions through multiple complementary approaches. Western blot analysis represents a quantitative method for measuring EP3 receptor protein levels before and after inflammatory stimulation, as demonstrated in studies with rat primary astrocytes where EP3 receptor expression significantly increased following lipopolysaccharide (LPS) treatment, providing direct evidence for inflammation-induced receptor upregulation . Immunohistochemistry and immunofluorescence techniques allow researchers to visualize the spatial distribution of EP3 receptor expression changes in intact tissues during inflammation, revealing not only altered expression levels but also potential changes in cellular localization or expression in previously negative cell populations . Flow cytometry using Anti-EP3 antibodies enables high-throughput quantification of receptor expression changes at the single-cell level across heterogeneous cell populations, allowing researchers to identify specific cell subtypes that modify EP3 expression in response to inflammatory stimuli. For in vivo inflammation models, researchers can employ time-course experiments with Anti-EP3 antibody staining at different stages of inflammation to track the temporal dynamics of receptor expression, providing insights into the role of EP3 signaling during inflammation initiation, progression, and resolution phases. Additionally, combining Anti-EP3 antibody detection with markers of inflammatory activation (such as cytokine expression or NF-κB nuclear translocation) through multi-label immunostaining can establish correlations between inflammatory signaling intensity and EP3 receptor regulation, helping to elucidate the molecular mechanisms governing inflammation-induced changes in receptor expression.

What are the methodological considerations for using Anti-EP3 antibodies in cancer research applications?

Using Anti-EP3 antibodies in cancer research applications requires careful attention to specific methodological considerations to generate reliable and clinically relevant data. Tissue sample preparation demands optimization for cancer specimens, as tumor tissues often contain heterogeneous cell populations, necrotic areas, and altered protein expression patterns; researchers should employ tissue microarrays with multiple tumor regions and matched normal tissues to comprehensively assess EP3 receptor expression patterns across cancer progression stages . Quantification methods should be standardized when comparing EP3 receptor expression between normal and cancerous tissues, with automated image analysis and scoring systems employed to minimize subjective interpretation; this approach is particularly important given findings of decreased EP3 expression in invasive bladder cancer compared to normal urothelial cells, indicating potential diagnostic or prognostic value . For mechanistic studies exploring EP3 receptor functions in cancer cells, researchers should complement antibody-based detection with functional assays measuring cell proliferation, migration, invasion, and apoptosis following receptor activation or inhibition to establish causal relationships between EP3 signaling and cancer phenotypes. Co-localization studies combining Anti-EP3 antibodies with markers for cancer stem cells, epithelial-mesenchymal transition, or tumor-associated immune cells can provide insights into the role of EP3 receptors in specific cancer-related cellular processes. Additionally, researchers should consider potential epitope masking or altered antibody accessibility in cancer tissues due to changes in protein glycosylation, phosphorylation, or interaction partners, which may necessitate multiple epitope-targeting antibodies or alternative detection methods to ensure comprehensive EP3 receptor profiling in oncological applications.

How can researchers effectively combine Anti-EP3 antibodies with other markers for co-localization studies?

Effectively combining Anti-EP3 antibodies with other markers for co-localization studies requires strategic planning and technical optimization to generate meaningful insights into receptor distribution and cellular context. Sequential immunostaining protocols offer a reliable approach for multi-label co-localization studies, particularly when primary antibodies are derived from the same species; researchers can apply the first primary antibody (Anti-EP3) followed by its secondary antibody, then block remaining binding sites before applying the second primary-secondary antibody pair, as successfully demonstrated in studies combining EP3 receptor detection with dopamine β-hydroxylase in catecholaminergic neurons . Careful antibody selection is essential, with researchers needing to verify that secondary antibodies show minimal cross-reactivity and that the selected fluorophores have well-separated excitation and emission spectra to prevent bleed-through during imaging, which is particularly important when studying structures with dense EP3 receptor expression such as the locus coeruleus . Confocal laser microscopy represents the preferred imaging method for co-localization studies due to its superior optical sectioning capabilities, allowing researchers to definitively establish whether EP3 receptors are expressed within specific cell types or subcellular compartments rather than in adjacent structures, as demonstrated in studies confirming EP3 receptor expression in dopamine β-hydroxylase-positive neurons . When designing experiments, researchers should include appropriate controls for antibody specificity (including peptide blocking controls) and fluorophore cross-talk, along with single-label controls to establish baseline signal intensities and distribution patterns for each marker individually . Quantitative co-localization analysis using specialized software can provide objective measures of spatial correlation between EP3 receptors and other markers, generating coefficient values that reflect the degree of co-localization and allowing statistical comparison between different experimental conditions or anatomical regions.

What emerging roles for EP3 receptors in neurological disorders could be investigated using Anti-EP3 antibodies?

The exploration of EP3 receptors in neurological disorders represents a frontier research area where Anti-EP3 antibodies could facilitate significant discoveries across multiple pathological contexts. Neuroinflammatory conditions present prime investigative targets given the robust EP3 receptor expression in monoaminergic nuclei and the observed upregulation in LPS-stimulated astrocytes, suggesting that Anti-EP3 antibodies could help elucidate how prostaglandin signaling contributes to neuroinflammatory cascades in conditions like multiple sclerosis, Alzheimer's disease, and Parkinson's disease . The extensive EP3 receptor expression in serotonergic neurons of the medulla oblongata (B1-B4) and select populations in other serotonergic groups (B5-B9) presents opportunities for investigating EP3 receptor involvement in mood disorders, particularly inflammation-associated depression, where Anti-EP3 antibodies could map receptor expression changes in relevant brain circuits following inflammatory challenges or in animal models of depression . Researchers could leverage Anti-EP3 antibodies to explore potential roles in epilepsy, based on preliminary findings of prostaglandin involvement in seizure susceptibility and the presence of EP3 receptors in cortical neurons, potentially revealing novel therapeutic targets for seizure control . The localization of EP3 receptors in the locus coeruleus and other catecholaminergic nuclei suggests possible involvement in attention-deficit disorders and cognitive dysfunction, areas where Anti-EP3 antibodies could help characterize receptor distribution in relevant neural circuits and track expression changes in developmental or acquired cognitive disorders . Additionally, given the role of prostaglandins in pain processing and the presence of EP3 receptors in pain-relevant neural circuits, Anti-EP3 antibodies could facilitate investigations into novel analgesic strategies targeting specific EP3-expressing neuronal populations in chronic pain conditions.

How might Anti-EP3 antibodies contribute to understanding the role of EP3 receptors in cancer progression?

Anti-EP3 antibodies can significantly advance understanding of EP3 receptors in cancer progression through multiple research approaches targeting key oncological processes. Comprehensive expression profiling across cancer types using tissue microarrays with Anti-EP3 antibodies could establish cancer-specific receptor expression patterns and identify correlations with clinical outcomes, building upon initial observations of reduced EP3 expression in invasive bladder cancer and providing potential prognostic biomarkers . Tumor microenvironment studies utilizing multi-label immunohistochemistry with Anti-EP3 antibodies alongside markers for immune cells, endothelial cells, and cancer-associated fibroblasts could reveal how EP3 receptor signaling influences the tumor stroma and immune infiltration, potentially uncovering mechanisms of immune evasion or angiogenesis regulation. Anti-EP3 antibodies could facilitate mechanistic investigations into how receptor signaling affects cancer cell behaviors through visualization and quantification of receptor expression following experimental manipulations of cancer-relevant pathways, helping to establish whether EP3 activation promotes or suppresses malignant phenotypes in specific cancer contexts . Examining EP3 receptor expression in cancer stem cell populations using Anti-EP3 antibodies combined with stem cell markers might reveal roles in tumor initiation and therapeutic resistance, potentially identifying novel targets for eliminating cancer-initiating cells. Additionally, tracking EP3 receptor expression changes during metastatic progression using Anti-EP3 antibodies in primary tumors, circulating tumor cells, and metastatic lesions could uncover involvement in invasion and colonization processes, potentially leading to new strategies for preventing cancer dissemination based on the manipulation of prostaglandin signaling pathways.

What technical innovations might improve the utility of Anti-EP3 antibodies in future research applications?

Future technical innovations could substantially enhance the utility of Anti-EP3 antibodies across diverse research applications through multiple advanced approaches. Development of phospho-specific Anti-EP3 antibodies that selectively recognize different phosphorylation states of the receptor would enable researchers to track receptor activation dynamics in real-time, providing insights into signaling kinetics and regulatory mechanisms beyond mere expression levels. Nanobody or single-chain variable fragment (scFv) derivatives of Anti-EP3 antibodies could offer superior tissue penetration and reduced background for high-resolution imaging applications, potentially enabling super-resolution microscopy of EP3 receptor distribution in cellular microdomains within complex tissues such as the brain . Multiplexed detection systems combining Anti-EP3 antibodies with other antibodies in highly parallelized immunostaining platforms (such as imaging mass cytometry or co-detection by indexing) would allow simultaneous visualization of EP3 receptors alongside dozens of other markers, facilitating comprehensive phenotyping of EP3-expressing cells in complex tissues. Genetically encoded intrabodies derived from Anti-EP3 antibodies could enable live-cell imaging of receptor trafficking and dynamics when fused with fluorescent proteins, providing unprecedented insights into receptor movement following ligand binding or during cellular responses to inflammatory stimuli . Additionally, developing bifunctional antibody constructs that combine EP3 receptor recognition with recruitment of effector molecules (such as ubiquitin ligases for targeted degradation) could create novel research tools for acute, specific disruption of EP3 signaling in selected cell populations, enabling precise dissection of receptor functions in complex physiological processes.

What are the key considerations for researchers selecting Anti-EP3 antibodies for their studies?

When selecting Anti-EP3 antibodies for research studies, scientists should evaluate multiple critical factors to ensure optimal experimental outcomes and reliable data generation. Epitope specificity represents a paramount consideration, with researchers needing to select antibodies targeting well-characterized epitopes like the peptide sequence (C)RAPHWYASHMKTR corresponding to amino acid residues 137-149 of the mouse prostanoid EP3 receptor, and confirming specificity through peptide competition assays that demonstrate signal ablation when the antibody is pre-incubated with the specific blocking peptide . Cross-species reactivity should be carefully assessed, particularly for comparative studies across model organisms, with the search results indicating that certain Anti-EP3 antibodies recognize the receptor across rat, mouse, and human samples, though validation in each specific species remains essential . Application compatibility must be confirmed for the intended experimental techniques, with documented evidence showing that some Anti-EP3 antibodies perform reliably in western blot analysis (1:200 dilution), immunohistochemistry (1:1000 dilution), and flow cytometry, though optimal conditions may vary between applications and require empirical determination . Lot-to-lot consistency should be evaluated through standardized quality control assays, especially for longitudinal studies where antibody performance stability is critical for reliable comparisons across time points. Additionally, researchers should consider published validation data showing the antibody's performance in relevant tissues and experimental conditions, such as the demonstrated ability to detect EP3 receptor expression changes in LPS-stimulated astrocytes or the clear immunoreactivity patterns observed in monoaminergic neurons, providing confidence in the antibody's ability to generate biologically meaningful data in similar experimental contexts .

How might the understanding of EP3 receptor biology impact future therapeutic development?

The evolving understanding of EP3 receptor biology holds significant promise for informing future therapeutic development across multiple disease areas through diverse mechanistic pathways. In pulmonary arterial hypertension, research has identified EP3 upregulation in pulmonary arterial smooth muscle cells under hypoxic conditions, suggesting that selective EP3 receptor antagonists could offer novel therapeutic approaches for this condition with limited treatment options . For neuropsychiatric disorders, the extensive mapping of EP3 receptors in monoaminergic nuclei, particularly serotonergic cells in the medulla oblongata and noradrenergic neurons in the locus coeruleus, provides anatomical substrates for developing targeted therapies that modulate these neurotransmitter systems through EP3 receptor manipulation, potentially addressing conditions like depression or anxiety with inflammatory components . In oncology, the complex and context-dependent roles of EP3 receptors in cancer progression, including observations of decreased expression in invasive bladder cancer, suggest that EP3-targeted therapies might need to be cancer-type specific, with potential applications in diagnostic biomarker development or as therapeutic targets in cancers where receptor signaling promotes malignant behaviors . For neuroinflammatory conditions, the documented upregulation of EP3 receptors in LPS-stimulated astrocytes indicates potential involvement in glial inflammatory responses, suggesting that EP3 modulators could help regulate neuroinflammation in conditions like multiple sclerosis, traumatic brain injury, or neurodegenerative diseases . Additionally, a systems biology approach to EP3 receptor signaling could facilitate the development of biased ligands that selectively activate beneficial signaling pathways while avoiding detrimental ones, potentially creating therapeutic agents with improved efficacy and reduced side effects compared to conventional prostaglandin modulators like non-steroidal anti-inflammatory drugs.